NCRI 2018 | Targeting TGF-β signaling in cancer

As a result of its opposing tumor promoting and suppressive abilities, transforming growth factor beta (TGF-β) and its pathways have provided potential opportunities for drug development. Carl-Henrik Heldin, PhD, from the Ludwig Institute for Cancer Research, Uppsala, Sweden, presents an exciting approach to inhibiting several stages of tumor progression via this molecule, which are being investigated in trials. Prof. Hendrick speaks at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK, on the state-of-the-art, novel data that contribute to our increasing knowledge of the role of TGF-β signaling in the development of cancer.